10-Q: Forte Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Forte Biosciences reports a net loss of $19.9 million for the first six months of 2024, while advancing its lead drug candidate, FB102, into patient studies.

Summary

• Forte Biosciences, a clinical-stage biopharmaceutical company, reported a net loss of $19.9 million for the six months ended June 30, 2024.
• The company's cash and cash equivalents stood at approximately $24.5 million as of June 30, 2024.
• Research and development expenses decreased to $10.1 million for the first six months of 2024, compared to $11.9 million for the same period in 2023, primarily due to a decrease in manufacturing costs.
• General and administrative expenses increased to $10.5 million for the first six months of 2024, compared to $4.0 million for the same period in 2023, primarily due to increases in legal and professional expenses.
• Forte is advancing its lead product candidate, FB102, a monoclonal antibody, into patient studies, with a focus on celiac disease.
• The company anticipates initiating patient-based studies in celiac disease in the third quarter of 2024, with top-line results expected by the second quarter of 2025.
• Forte believes its existing cash and cash equivalents will be sufficient to fund operations for at least 12 months from the filing date of this report.
• The company expects to incur ongoing losses as it continues to develop FB102 and may need to raise additional capital in the future.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making progress in its clinical development, the significant losses, increased expenses, and need for additional capital raise concerns. The ongoing legal proceedings and Nasdaq non-compliance add to the negative sentiment.

Positives

• Forte is advancing FB102 into patient studies, marking a significant step in its clinical development.
• The company has sufficient cash to fund operations for at least the next 12 months.
• The company has completed phase 1 trials of FB102 in healthy volunteers.
• The company has identified a potential market for FB102 in celiac disease, vitiligo, type 1 diabetes, graft-versus-host disease and alopecia areata.

Negatives

• Forte has incurred significant net losses since its inception and expects to continue to incur losses.
• The company's general and administrative expenses have increased significantly.
• Forte is dependent on the success of a single product candidate, FB102.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms.
• The company is currently non-compliant with Nasdaq's minimum bid price requirement, which could result in delisting.

Risks

• Forte's business is heavily reliant on the success of FB102, which is still in early clinical development.
• The company has a limited operating history and has incurred net losses since inception.
• Forte will require additional capital to fund its operations and may not be able to obtain it on acceptable terms.
• Clinical development is a lengthy and expensive process with uncertain outcomes.
• The company faces significant competition from other healthcare companies.
• The market opportunities for FB102 may be limited and estimates of target patient populations may be inaccurate.
• Forte is currently non-compliant with Nasdaq's minimum bid price requirement, which could result in delisting.
• The company is subject to risks associated with public health threats and epidemics.
• The company is subject to risks associated with legal proceedings.

Future Outlook

Forte expects to incur ongoing losses as it continues to develop FB102 and may need to raise additional capital in the future. The company anticipates initiating patient-based studies in celiac disease in the third quarter of 2024, with top-line results expected by the second quarter of 2025.

Management Comments

• Management expects to continue to incur additional losses in the foreseeable future as the Company continues its development efforts on advancing FB102 through clinical trials.
• The Company believes that its existing cash and cash equivalents will be sufficient to allow the Company to fund its operations for at least 12 months from the filing date of this Form 10-Q.

Industry Context

Forte is operating in the competitive biopharmaceutical industry, focusing on autoimmune and autoimmune-related diseases. The company's development of FB102 is aimed at addressing key pathways implicated in these indications. The report highlights the challenges and uncertainties associated with drug development, including the need for significant capital and the risk of clinical trial failures.

Comparison to Industry Standards

• Forte's financial results are typical for a clinical-stage biopharmaceutical company, with significant losses and reliance on external funding.
• The decrease in research and development expenses is primarily due to a decrease in manufacturing costs, which is common as companies move from preclinical to clinical stages.
• The increase in general and administrative expenses is also typical for a company that is scaling up its operations and facing increased legal and professional costs.
• The company's cash position is relatively low compared to other companies in the industry, which highlights the need for additional capital.
• The company's focus on FB102 is similar to other companies that are developing monoclonal antibodies for autoimmune diseases, such as AbbVie's Rinvoq and Bristol Myers Squibb's Orencia, but these companies are much larger and have more resources.
• The company's timeline for initiating patient studies in celiac disease and expecting top-line results is consistent with the timelines of other companies in the industry.

Legal Proceedings

• The company was involved in a legal proceeding, Camac Fund L.P. v. Forte Biosciences Inc., which was dismissed with prejudice on July 29, 2024.
• The company was involved in a legal proceeding, Camac Fund, LP v. Paul A. Wagner, et al., which is ongoing.
• The company was involved in a legal proceeding, Forte Biosciences, Inc. v. Camac Fund, LP, et al., which was dismissed with prejudice on June 11, 2024.

Related Party Transactions

• One member of the Company's board of directors received cash payments of $100 thousand and $129 thousand for scientific consulting services during the three and six months ended June 30, 2024, respectively.
• The Company had a $50 thousand payable to the director as of June 30, 2024 included in accrued liabilities.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential cost-cutting measures if the company's financial situation does not improve.
• Customers (potential patients) may benefit from the development of FB102 if it proves to be effective and safe.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• Initiate patient-based studies in celiac disease in the third quarter of 2024.
• Continue to develop FB102 for other autoimmune and autoimmune-related indications.
• Potentially raise additional capital through equity or debt financings or strategic partnerships.
• Continue to monitor the potential impacts of global events on the business.

Key Dates

Keywords

FB102, clinical-stage, biopharmaceutical, monoclonal antibody, autoimmune, celiac disease, clinical trials, research and development, financial results, Nasdaq, capital raise